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Abstract
Background: Differential mRNA splicing and alternative promoter usage of the TP73 gene results
in the expression of multiple NH2-truncated isoforms that act as oncogenes. Abundant levels of
these p73 variants in a variety of human cancers correlated with adverse clinical prognosis and
response failure to conventional therapies, underscoring their relevance as marker for disease
severity and target for cancer intervention. With respect to an equally important role for amino-
truncated p73 splice forms (ΔTAp73) and ΔNp73 (summarized as DNp73) in the tumorigenic
process, we designed locked nucleic acid (LNA) antisense oligonucleotide (ASO) gapmers against
individual species that were complementary to ΔEx2 and ΔEx2/3 splice junctions and a region in
exon 3B unique for ΔN' and ΔN.
Results: Treatment of cancer cells with these ASOs resulted in a strong and specific reduction of
tumorigenic p73 transcripts and proteins, importantly, without abolishing the wild-type p73 tumor
suppressor form as observed with p73-shRNA. The specific antisense oligonucleotides rescued
cells from apoptosis inhibition due to overexpression of their corresponding amino-truncated p73
isoform and decreased tumor cell proliferation. Furthermore, ASO-116 against ΔEx2/3 coupled to
magnetic nanobead polyethyleneimine (MNB/PEI) carriers significantly inhibited malignant
melanoma growth, which correlated with a shift in the balance between endogenous TAp73 and
ΔEx2/3 towards apoptotic full-length p73.
Conclusion: Our study demonstrates the successful development of LNA-ASOs that selectively
differentiate between the closely related p73 oncoproteins, and provide new tools to further
delineate their biological properties in different human malignancies and for therapeutic cancer
targeting.
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The human p73 is a member of the p53 tumor suppressor
family, based on substantial structural and functional
homologies. Unlike p53, p73 is rarely mutated in human
cancers [1]. As an early-recognized feature, the TP73 gene
produces multiple transcripts with opposing functions. A
detailed analysis of p73 in tumor cells revealed the pres-
ence of multiple N-terminally truncated isoforms (ΔN,
ΔN', ΔEx2, ΔEx2/3; collectively called DNp73), which lack
all or most of the transactivation domain that accounts for
the tumor suppressor function of the full-length TAp73
protein. While the ΔNp73 transcript is generated from a
cryptic promoter in intron 3, the majority of the amino-
truncated p73 variants is produced by alternative exon
splicing from the E2F1 responsive promoter in the 5'UTR
upstream of the non-coding exon 1. All isoforms fail to
induce cell cycle arrest and apoptosis. In addition, they act
as dominant-negative competitors for DNA binding and/
or heteroduplex formation with p53 and wild-type
TAp73, and confer drug resistance to tumor cells harbour-
ing wild-type p53 and/or TAp73 [2,3]. We also demon-
strated that the ΔEx2/3 isoform inactivates functions of
the retinoblastoma (RB) tumor suppressor protein in cell
cycle and differentiation control [4,5]. By inactivating
both major tumor suppressor pathways in human cells
they are functionally analogous to several viral oncopro-
teins. In this sense, overexpression of ΔEx2/3 and ΔN has
been shown to transform fibroblasts to tumorigenicity in
nude mice [6,7], and drive carcinogenesis in transgenic
mice in vivo [8].
NH2-truncated p73 forms were found frequently elevated
in various types of tumor cells and primary malignancies
from patients, but not in the surrounding normal tissues
[9]. Beyond, increased DNp73 expression levels are
strongly associated with a worse recurrence-free and over-
all survival of patients, and poor prognosis features such
as lymph node metastasis and vascular invasion [10]. Spe-
cifically, overexpression of ΔEx2/3p73 and ΔNp73 was
associated with advanced pathologic tumor stages. Like-
wise, alterations in the relative levels of TAp73 and the
apparently tumor-specific aberrant expression of individ-
ual oncogenic p73 species, that might account for a shift
in the net function of p73 from proapoptotic to prosur-
vival, have been shown to correlate with prognosis in
some cancers. All this strongly underscores that the
expression pattern of NH2-truncated p73 is an important
determinant of tumor development and the cellular
response to treatments, making it a biological relevant tar-
get for cancer prevention and therapy.
Although there is increasing evidence for an equally
important role of individual amino-terminal p73 splice
variants and ΔNp73 in the tumorigenic process, we are
currently unable to evaluate their oncogenic potency
under physiological conditions in vivo. The aim of our
study was to develop mono-specific inhibitors for the
majority of NH2-truncated alternative-spliced p73 iso-
forms that allow differential knockdown of all closely
related oncoproteins in growing human tumors.
Methods
Cell Culture, Viruses and Fluorescence Microscopy
Human H1299 lung cancer cells, human embryonic kid-
ney HEK 293 cells, and human WI-38 lung fibroblasts
were maintained in Dulbecco's Modified Eagle Medium
(DMEM; Invitrogen, Karlsruhe, Germany) supplemented
with 10% fetal calf serum (Biochrom, Berlin, Germany).
Human SK-Mel-29 melanoma cells were cultured in
DMEM containing sodium pyruvate. Medium contained
2 mM L-glutamine, 100 μg/ml penicillin, 100 U/ml strep-
tomycin, and 1,25 μg/ml amphotericin B. The adenoviral
(Ad) vectors Ad-shGFP and Ad-shp73 have been
described elsewhere [11]. Adenovirus infection was car-
ried out at a multiplicity of infection (MOI) that allows
100% transduction of target cells. FITC and GFP imaging
was performed by fluorescence microscopy at indicated
time points.
Antisense Oligonucleotides, shRNA and Transient 
Transfections
Oligonucleotide (ON) LNA modifications and FITC-labe-
ling was conducted by BioTeZ GmbH. ASO sequences
were the following: ASO-115 5'-CTGTCTGGTTCCCT-
GCAGCC-3', ASO-116 5'-GATTGAACTGGGCCTGCAGC-
3', and ASO-185/451 5'-GGAACTGGTGTCCCGTGGGA-
3' (LNA bases are bold). The non-sense control ON (nsc)
with 5'-TAACCGTTTCTTCCTCGTCC-3' serving as a nega-
tive control was verified by NCBI blastn search. For in vivo
experiments a scrambled ON (sc) to ASO-116 with the
same base content was generated using the siRNA Wiz-
ard™ platform at http://www.sirnawizard.com (ASO-sc:
5'-GCCCAGAAGGTGCCTAGGTT-3'). ASO transfections
were performed with Lipofectamine 2000 (Invitrogen,
Karlsruhe, Germany). Cotransfection experiments were
carried out with 2 μg plasmid mixed with respective
amounts of antisense molecules. Plasmid encoding
shRNA was transfected using Effectene (Qiagen, Hilden,
Germany). The RNA interference target sequence was 5'-
GGCCATGCCTGTTTACAAG-3'.
Quantitative Real-Time PCR (qPCR)
Total RNA was extracted with the NucleoSpin Kit (Mach-
erey-Nagel, Düren, Germany) and reverse transcribed
with Omniscript RT (Qiagen, Hilden, Germany) using
Oligo(dT)18 primer. The cDNA sample was mixed with iQ
SYBR Green Supermix (Biorad, München, Germany).
QRT-PCR was performed on iQ5 Multicolor Real-Time
PCR Detection System (Biorad, München, Germany)
using 1/10 volume of RT reaction. Relative gene expres-Page 2 of 13
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Primer sequences are available upon request.
Western Blotting
Cells were lysed in RIPA buffer (50 mM Tris-HCl (pH 7.2),
150 mM NaCl, 1% sodium deoxycholate, 0.1% SDS,
0.1% Triton X-100, 5 mM EDTA) supplemented with pro-
tease inhibitor mixture Complete Mini (Roche Applied
Science, Mannheim, Germany) and total protein concen-
tration was quantified by a modified Bradford assay.
Equal amounts of protein were separated by SDS-PAGE,
transferred to nitrocellulose membranes, and probed with
anti-p73 ER-15 (BD Biosciences, Heidelberg, Germany),
anti-ΔNp73 (Imgenex, San Diego, CA, USA) or anti-β-
Actin (Sigma-Aldrich, Taufkirchen, Germany). Primary
antibodies were detected with appropriate secondary anti-
body-horseradish peroxidase conjugates according to the
enhanced chemoluminescence protocol.
Hoechst 33342 Staining and Caspase-3 Activity
After treatment, cells were incubated with Hoechst 33342
at 1 μg/ml for 15 min and subjected to fluorescence
microscopy. Hoechst-stained cells were harvested, coun-
terstained with 10% trypan blue solution, and counted in
a hämcytometer. Caspase-3 activity was assayed using the
ApoAlert kit (Takara Bio, Saint-Germain-en-Laye, France)
as described by the manufacturer. Absorbance was meas-
ured at 405 nm in a spectrophotometer.
Cell Proliferation Assay
Cells were seeded at a density of 5 × 104, serum-starved for
24 h, and transfected with PEI-ASO complexes at day 1
and 3 after plating. DNA synthesis was measured by Cell
Proliferation BrdU (5-bromo-2'-deoxyuridine)-ELISA
(Roche Applied Science, Mannheim, Germany) according
to the instructions.
Magnetic Nanobead (MNB)/Polyethyleneimine (PEI)/DNA 
Complex Formation
Branched PEI (average MW 25 000) (Sigma-Aldrich,
Taufkirchen, Germany) was purified through dialysis in
three changes of a 100-fold volume excess of water,
lyophilized and re-hydrated before use. PEI/ASO com-
plexes were prepared at the N/P ratio of 8. The PEI solu-
tion and DNA solution at a given N/P ratio were diluted
in 5% glucose to ensure iso-osmolarity for transfection
experiments and in vivo application. PEI was added to
DNA and immediately mixed and incubated for 30 min at
RT. For intratumoral injections, PEI/ASO complexes were
conjugated with streptavidin-coated magnetic nanobeads
(MNBs) (Promega, Mannheim, Germany) by vortexing
for 30 s followed by incubation at RT for 30 min. The
resulting MNB/polymer/ASO complexes are stable in
aqueous solution and can be stored at 4°C for several
days.
Animal Experiments and In Vivo Imaging
Tumors were established by subcutaneous (s.c.) injection
of 107 SK-Mel-29 cells into the rear flanks of 6- to 8-week-
old female athymic nu/nu mice. Animals with palpable
tumors were randomized in three groups to ensure uni-
form distribution: Group A untreated control (n = 9
tumors), group B treated with PEI/ASO-sc (n = 8 tumors),
and group C treated with PEI/ASO-116 (n = 13 tumors).
For magnetic force transduction, animals with tumors of
diameter >8 mm were randomized into two groups
(group D: MNB/PEI/ASO-sc, n = 6 tumors; group E: MNB/
PEI/ASO-116, n = 10). Mice were anaesthetized by intra-
peritoneal injection of body-weight adapted doses of 10%
ketamine and 2% xylazin. Oligonucleotide complexes
were intratumorally administered at 1.5 mg/kg/day. In
magnetic bead guided experiments, a magnet sized 4 × 1
mm with 1.41–1.45 T was placed closely adjacent to the
tumor. Tumor volumes were measured with calipers and
calculated from the longest diameter and average width
by assuming a prolate spheroid shape (tumor volume = π/
6 × (large diameter × [shortdiameter]2). The relative
tumor volume (RTV) was determined using RTV = Vi/V0,
where Vi is the daily-measured tumor volume and V0 is the
initial tumor volume. After treatment, mice were sacri-
ficed and representative tumor specimen of each experi-
mental group were dissected. Total RNA was extracted and
quantities of ΔEx2/3p73 and TAp73 transcripts were
determined by qPCR. All animal procedures were con-
ducted in adherenceto ethical standards and with
approval of the local Animal CareCommittee.
For fluorescence detection, PEI was labeled by Oregon
green 488 Protein labeling kit (Invitrogen, Karlsruhe, Ger-
many) and injected intratumorally into mice. In vivo
imaging was performed at 1, 8 and 24 h after injection.
Images were acquired using NightOwl LB981 imaging sys-
tem (Berthold Technologies, Bad Wildbad, Germany)
with an exposure time of 100 s. For colocalization of the
fluorescent image on the animal body, gray scale and
pseudocolor images were merged. Quantification of sig-
nal intensity in all animals was performed by WinLight32
Software.
Computational Analysis and Secondary Stucture 
Predictions
Human genomic sequences for the 5'UTRs of TP73 tran-
scripts were obtained from ENSEMBL database. The bind-
ing energies as well as the propability matrices for single-
stranded target sequences were calculated using the Sfold
server application module Soligo. Each N-terminal p73
transcript was calculated with the C-terminal configura-
tions α, β, γ and δ, and their propability diagrams were
merged at the indicated nucleotide positions. In silico sec-
ondary structure prediction was carried out using the CLC
RNA Workbench Software (CLC Bio, Aarhus N, Den-Page 3 of 13
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configurations α, β, γ, δ and ε were used to calculate the
mRNA structure. The respective ASO epitopes at the N-ter-
mini of these mRNAs were then compared for structural
identity in the ASO target sequence.
Statistical Analysis
Statistical analysis of tumor growth in nude mice was per-
formed with one-way analysis of variance (ANOVA). Var-
iances in BrdU incorporation, caspase activation and
viable cell counts were compared with an unpaired Stu-
dent's t-test (two-sided).
Results and Discussion
Design of LNA-DNA gapmers against oncogenic NH2-
truncated p73 isoforms
Differential mRNA splicing and alternative promoter
usage of the human TP73 gene results in the expression of
multiple N-terminally truncated forms (ΔEx2, ΔEx2/3,
ΔN', ΔN; Figure 1A) that act as oncogenes. Current evi-
dence suggests an equally important role for individual
p73 splice variants and ΔNp73 in the tumorigenic process,
but there is no attempt so far for their selective silencing
without concomitant reduction of the apoptotic TAp73
form. In order to develop mono-specific inhibitors for
each amino-terminal isoform, we used a modified anti-
sense technology. According to previous reports indicat-
ing that ONs with locked nucleic acids (LNA) at their 3'-
and 5'-ends efficiently recruit RNase H and promote deg-
radation of target RNA [12,13], we designed 20-mer LNA-
DNA gapmers with a central DNA region of 12 nucle-
otides and 3'-5' ends of four LNA monomers. LNA bases
have been shown to confer resistance to nucleases when
incorporated at the 5' and 3' ends of oligomers [14]. Anti-
sense specificity for ΔEx2p73 and ΔEx2/3p73 was
achieved by using the splice junction of each exon dele-
tion variant (Figure 1B). The ASO targeting ΔN' and ΔN
was directed against a region in the intron-derived exon
3B, which is unique to both isoforms.
The optimal target sequence was determined in silico by
three parameters: (a) a probability profile for single-
stranded regions in the mRNA, which serve as docking sta-
tions for initial oligo annealing [15,16], (b) a minimum
free energy model of the secondary structure of the mRNA
with a more recent compilation of Turner's free energy
parameters [17], and (c) the binding energies for a given
ASO sequence on the mRNA [18]. The probability plot for
ΔEx2p73 mRNAs indicates single-strands downstream of
nucleotide (nt) position 120 and around position 130
[see Additional file 1A]. This was confirmed by secondary
structure prediction for ΔEx2p73 transcripts, where two
bulges of more than 4 bases were present at positions 121
and 130, exposing the splice junction for oligo binding
[see Additional file 1E]. Since mRNA 3D-structure
depends predominantly on nearest neighbour interac-
tions, alterations in the C-terminus may affect folding of
N-terminal domains [19]. Therefore, structure predictions
were carried out for several C-terminal isoform configura-
tions. Binding energies for ASO-115 (number indicates
starting base of ASO position on the mRNA) targeting
ΔEx2p73 mRNA reached values around -8 kcal/mol [see
Additional file 2]. According to the Soligo algorithm using
≤ -8 kcal/mol as default filter criteria for potent ASOs, the
values for ASO-115 were considered sufficient. Similar
results were obtained for ASO-116. Analysis for single-
stranded sections revealed a high probability for unpaired
mRNA at the splice junction of ΔEx2/3p73 transcripts,
which was confirmed by the predicted structure model
[see Additional file 1B, F]. In the ΔNp73 and ΔN'p73 ASO,
where the target region is of different location in each
transcript owing to distinct transcriptional and mRNA
maturation processes, ASO-185/451 denotes the starting
positions for the ON in both isoforms. The probability
plots and secondary structures of ΔNp73 showed the min-
imum of 4 unpaired bases, which are sufficient for initial
oligo annealing [see Additional file 1C, G] [19]. Likewise
the predicted epitopes and probability plots for ΔN'p73
transcripts suggest mRNA accessibility at the target region
of ASO-185/451 [see Additional file 1D, H].
ASOs induce selective suppression of target RNAs
To ensure efficient internalization of the ASOs into target
cells, we determined the amount of oligonucleotide
uptake after 8, 16 and 24 h of transfection using a concen-
tration range between 100–250 nM fluorescein isothiocy-
anate (FITC) labeled ASO. All LNA-DNA gapmers showed
a similar high transfection efficiency in HEK293, H1299,
and SK-Mel-29 cells overexpressing individual DNp73
isoforms, and similar intracellular distribution patterns
with clear nuclear, perinuclear, and diffuse cytosolic stain-
ing (data not shown). The capacity and specificity of the
designed antisense gapmers to reduce endogenous levels
of ΔEx2, ΔEx2/3, ΔN', and ΔN transcripts was subse-
quently analyzed by qRT-PCR in HEK293 containing all
N-terminally truncated isoforms at higher levels (Figure
2A). Based on previous results indicating that RNase H
enzymatic activity is stimulated as early as 1 h after ASO
treatment [20], antisense molecules were transfected at a
concentration of 250 nM into HEK293 cells and gene
silencing efficiencies have been monitored over 2, 4, and
6 h after treatment. The effect of a non-sense control ON
is shown for comparison. In these cells, ASO-115, 116,
and 185/451 directed against the splice forms ΔEx2, ΔEx2/
3 or ΔN' induced the strongest antisense effect after 6 h
compared to the nsc-gapmer. At this time point, we meas-
ured a 35- to 45-fold reduction of gene expression for
both ASO-115 (Figure 2B) and ASO-116 (Figure 2C),
whereas ASO-185/451 promoted a weaker (5-fold) but
still significant suppression of the ΔN' mRNA (Figure 2D).Page 4 of 13
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Site-directed targeting of NH2-truncated p73 mRNAs by LNA gapmersFigure 1
Site-directed targeting of NH2-truncated p73 mRNAs by LNA gapmers. (A) Structure of the human TP73 gene. 
Exons are shown as boxes and structured according to the domain: transactivation domain (blue); exon 3B-derived coding 
sequence (purple); DNA-binding domain (red); oligomerization domain (yellow); COOH terminus (green). C-terminal splice 
variations are indicated. The transcriptional start sites of the two promoter regions (TA-promoter, ΔN-promoter) are marked 
by arrows. Aberrantly spliced transcripts regulated by the TA-promoter are labeled ΔEx2, ΔEx2/3, and ΔN'. The unique 5' 
untranslated region of the ΔN transcript is colored grey. (B) Binding sites of gapmer ASOs in different DNp73 transcripts. 
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Efficacy and specificity of ASOs for endogenously upregulated p73 transcriptsFigure 2
Efficacy and specificity of ASOs for endogenously upregulated p73 transcripts. (A) Quantitative RT-PCR of endog-
enous expression of TAp73 and amino-truncated p73 transcripts relative to p53 and p63 in HEK293 cells. The broken line indi-
cates the baseline level of DNp73 transcripts. Cells were transfected with 250 nM of ASO-115 (B, F), ASO-116 (C, G), and 
ASO-185/451 (D, E, and H). Antisense effects on transcript levels were quantitated by real-time PCR at indicated time points 
after treatment. Fold expression was calculated after normalization with RPS9 relative to non-specific control-ASO (nsc). 
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ASO-185/451 antisense gapmer against its second target
transcript, revealed a substantially higher inhibitory effect
with a more than 2000-fold reduction of the ΔN mRNA
level already 2 h following treatment relative to the nsc-
ASO (Figure 2E). Repeated experiments provided similar
results with rendering the ΔNp73 transcript barely detect-
able during the first 4 h post transfection. The following
time points showed a constant 225- and 279-fold sup-
pression, suggesting a prolonged duration of gene silenc-
ing upon amplified initial repression intensity.
The main goal of our study was to design ASOs that allow
specific knockdown of individual oncogenic p73 forms.
As demonstrated in Figure 2F, ASO-115 induced a com-
plete decrease of ΔEx2p73 mRNA to 0.03% of the control,
whereas expression of TAp73 and other non-targeted p73
variants remained largely unaffected. Similar data was
obtained with the ASO-116 against ΔEx2/3p73 (Figure
2G). Interestingly, both ASOs targeting the splice junction
of exon 1 have very little effect on ΔNp73 transcripts,
which lack exons 1 to 3 due to alternative promoter usage.
Analogous to this, ASO-185/451 revealed no silencing
impact on the ΔEx2 and ΔEx2/3 transcripts because of the
absence of exon 3B in these variants (Figure 2H). These
results indicate that all developed ASOs exhibit a selec-
tively high inhibitory efficiency against their target, result-
ing in no or low knockdown of other p73 isoforms.
Comparable high isoform-specific knockdown activities
of these ASOs were also observed in H1299 tumor cells
with amino-truncated p73 transcripts upregulated [see
Additional file 3].
Effect of site-directed targeting on DNp73 protein level
As endogenous levels of all amino-truncated p73 proteins
are hardly detectable in a single cell line, expression plas-
mids containing the transcript-specific 5'UTRs for the dis-
tinct isoforms were cotransfected with 500 nM of the
antisense molecules into H1299 cells and analyzed by
Western blot. Due to the inherently high stability of the
oncogenic proteins, we measured their level in specific
LNA gapmer- and control ON-treated cells after 24 h. The
levels of full-length TAp73 and DNp73 forms in H1299
cells treated with LNA-DNA are shown in histograms. Fol-
lowing a single transfection, ASO-115 strongly reduced
the level of ΔEx2p73 protein up to 30% of control, but not
TAp73 (Figure 3A). A nearly complete disruption of the
ΔEx2/3p73α protein to less than 5% of the nsc-oligonu-
cleotide was achieved by the treatment with ASO-116.
ASO-185/451 but not the negative nsc-ASO significantly
suppressed both targets on protein level, although protein
derived from the ΔNp73α plasmid was reduced more effi-
ciently than ΔN'. These findings correlate with the
obtained qPCR results, where ASO-185/451 targeting
ΔNp73 and ASO-116 directed against ΔEx2/3 showed the
strongest suppression activity. In addition, we cotrans-
fected the two different amino-terminal isoforms ΔEx2/3
and ΔNp73 along with one of the antisense molecules. As
demonstrated in Figure 3B, ASO-116 and vice versa ASO-
185/451 inhibited their target in a highly specific manner,
while protein expression of the second ΔNp73 or ΔEx2/
3p73 isoform in each case remained unchanged. Impor-
tantly, consistent with the PCR data, none of the designed
LNA gapmers against the oncogenic variants of p73 has an
obvious effect on the amount of TAp73 protein (Figure
3A).
This is in sharp contrast to the effect of a p73-shRNA. The
use of RNAi is restricted to sequences that fullfill special
criteria, such as the GC content, A at position 19 or
absence of internal repeats [21]. According to these
parameters, the target sequence of the p73-shRNA is
located in exon 5 of the transcript. In contrast to the data
observed with the NH2-truncated isoform-specific gap-
mers, transfection of HEK293 cells with a plasmid encod-
ing shRNA against p73 resulted in a general silencing of
TAp73 and oncogenic forms up to 80% of the scrambled-
shRNA, with the strongest potency against the wildtype
transcript (Figure 3C, upper panel). This unspecific inhib-
itory effect was also confirmed on protein level. In H1299
cells infected with an adenoviral vector expressing p73-
shRNA, we found all N-terminal isoforms and TAp73
equally suppressed at 48 h after infection (Figure 3C, bot-
tom panel) compared to the control virus Ad-shGFP.
From these results, we conclude that site-directed target-
ing of ΔEx2 and ΔEx2/3 splice junctions and a unique
region in Exon3B for ΔN' and ΔN by antisense ON is a fea-
sible technique for selective knockdown of individual p73
oncogenes.
Antitumorigenic activity of DNp73 ASOs
Previous studies have shown that NH2-truncated p73 spe-
cies inhibit apoptosis by p53 and TAp73 in cancer cells
[3,7,22]. Consequently, the proapoptotic function of
these proteins could be restored by depleting the pool of
antagonistic p73 proteins. After having shown that the
designed ASOs specifically silence DNp73 forms, we
determined whether they also influence cellular survival.
Figure 4A shows that ΔEx2/3p73α and ΔNp73α overex-
pression markedly reduced the response of normal fibrob-
lasts to genotoxic damage induced by doxorubicin
compared to pcDNA3.1 + ASO-nsc treated cells with clear
apoptotic features. In contrast, the apoptosis antagonizing
effect of both oncogenic p73 forms significantly declined
after cotransfection of their specific ASO resulting in
increased cell killing over time. Accordingly, while the
DNp73 isoforms partially rescued WI-38 cells from DNA
damage, isoform-specific ASOs substantially enhanced
caspase 3 activity (Figure 4B).Page 7 of 13
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Knockdown effect of NH2-isofom specific ASOs on protein level compared to p73-shRNAFigure 3
Knockdown effect of NH2-isofom specific ASOs on protein level compared to p73-shRNA. (A) Western blot anal-
ysis showing the levels of full-length TAp73 and amino-truncated p73 forms 24 h following cotransfection of 2 μg p73 expres-
sion plasmids and 500 nM antisense or nsc LNA-DNA gapmers. Actin was used as a loading control. Protein bands were 
quantitated in relative software units by the Bio-Imaging-Analyzer (Fuji) using the TINA program (shown as fold induction or 
reduction, respectively, normalized to actin control bands. (B) Protein levels of ΔEx2/3 and ΔNp73 in H1299 cells cotrans-
fected with ΔEx2/3p73 and ΔNp73 expression plasmids along with ASO-116 (left) or ASO-185/451 (right) compared to con-
trol-ASO. Relative densitometric units analyzed as described in A are shown in the bottom panel. (C) QPCR indicating the 
endogenous expression levels of p73 isoform mRNAs normalized to RPS9 in HEK293 cells at 48 h after transfection with 1 μg 
p73-shRNA encoding plasmid relative to levels in control sh-sc treated cells (set as 1). Bar graphs show results from three 
independent experiments. Data are the mean ± SD. Immunoblot of H1299 cells with endogenous ΔN levels and transfected 
with 1 μg of expression plasmids for TAp73, ΔEx2, and ΔEx2/3. Cells were treated with Ad-shp73 or Ad-shGFP at moi 20. 
Forty-eight hours after infection, cells were lysed, and extracts were probed with anti-p73 (ER-15) antibody. β-actin was used 













































Molecular Cancer 2009, 8:61 http://www.molecular-cancer.com/content/8/1/61Finally, in an effort to corroborate the role of single
amino-truncated p73 species in the tumorigenic process,
we tested DNp73-specific ASOs in tumor xenografts estab-
lished from SK-Mel-29 melanoma cells. These rapidly
growing tumors, exhibiting major defects in p53 related
apoptosis pathways [23], were selected for our studies due
to their high level expression of endogenous ΔEx2/3 (Fig-
ure 5A), which has so far been implicated in the induction
of tumor growth when overexpressed [7,8]. For efficient
delivery of antisense molecules, ASO-116 was complexed
to synthetic nanopolymer PEI [24]. Analysis of the PEI/
ASO-116 polyplexes in cultured SK-Mel-29 cells showed a
strong 6-to 9-fold decrease of target mRNA level after
transfection (Figure 5B). This inhibitory effect on ΔEx2/
3p73 expression was associated with a significantly
reduced proliferation rate by PEI-ASO-116 over 5 days
compared to untreated or PEI/ASO-sc treated cells as dem-
onstrated by BrdU-ELISA (Figure 5C). Our data confirm
that p73 species-specific ASOs conjugated to PEI are bio-
logically active. Using fluorescence-labeled PEI/ASO-116,
signal intensity peaked at 1 h after intratumoral injection,
indicating ASO distribution within the whole tumor (Fig-
ure 5D). Although the complex decreased over time, a sta-
bil fraction remained detectable in the tumor after 24 h,
which is sufficient to ensure continuous availability of
ASO over the treatment period at daily administration.
In order to improve in vivo administration, magnetic
nanobeads (MNBs) were used to prevent diffusion of the
coupled PEI/ASO complex from the injection site, and
PEI/ASO-116 coated to MNBs versus PEI/ASO-116 alone
were tested for their antitumoral effect in presence of a
magnet implanted near the tumors. Consistent with the
inhibitory effect on cell proliferation illustrated in Figure
5C, tumor growth curves revealed a robust decrease in
growth rates when treated with ASO-116 independent of
the mode of delivery (Figure 5E). However, with increas-
ing treatment tumors injected with ASO-116 under mag-
netic force-guidance were significantly smaller than those
treated with PEI/ASO-116 alone. This demonstrates that
by keeping the ASO concentrated in the tumor, we could
enhance its specific therapeutic efficacy. Quantification of
p73 transcripts in the tumors after final injection revealed
an equally strong suppression of ΔEx2/3p73 for the PEI-
and MNB/PEI-delivered antisense oligonucleotide (8.5-
fold and 7-fold) compared to the control groups (Figure
5F). Of note, enforced antitumorigenic activity of ASO-
116 directly correlated with the upregulation of the tumor
suppressive TAp73 form, which showed a more than 2
times higher increase when tumors were subjected to
magnetic force-guided ASO-116 treatment. These data
suggest that inhibition of TAp73 in response to increased
ΔEx2/3p73 expression in growing tumors is the mecha-
nism responsible for ΔEx2/3p73-mediated tumor growth.
Based on present studies, NH2-truncated p73 isoforms are
upregulated in the majority of tumors with a concomitant
rise of TAp73 [9], suggesting that the specific ratio
between the apoptotic TAp73 form and different domi-
nant-negative p73 variants determines the functional out-
come of p73 and the cell fate. In fact, alterations in the
relative levels of truncated p73 and TAp73 and/or p53 cor-
relate with therapy failure and poor prognosis in many
cancers [10,25,26]. In this regard, downregulation of the
ΔNp73 species by antisense technique has been shown to
alleviate its suppressive action and to enhance p53/
TAp73-mediated apoptosis in cancer cells in response to
chemotherapy [3]. In turn, mice harbouring a specific
knockout of TAp73 are tumor-prone and sensitive to car-
cinogens. Tomasini et al. reported that 73% of TAp73-/-
mice spontaneously develop malignancies, thereby estab-
lishing TAp73 isoforms as bona fide tumor suppressors
[27]. Furthermore, this group showed that TAp73 is regu-
lating the spindle assembly checkpoint (SAC) complex,
suggesting that SAC impairment leads to genomic insta-
bility and aneuploidity in TAp73-deficient cells. Hence,
the ability to induce and maintain proper mitotic arrest
could be a mechanism of TAp73-mediated anti-tumori-
genicity [28]. Both studies emphasize the functional
importance of an imbalanced TAp73:DNp73 ratio. Taking
into account that the expression levels of individual
DNp73 species might be tumor-specific and particularly
alternative-spliced isoforms ΔEx2/3, ΔEx2, and ΔN' that
mimic the TAp73 knockout are predominantly expressed
in many cancers including malignant melanoma [10,29-
33] rather than ΔNp73, specific inhibitors for these poten-
tial oncogenes are needed. In this study, we show that
selective knockdown of a single p73 splice product leads
to the inhibition of melanoma tumor growth, and at the
same time to the induction of TAp73, underscoring that
the ratio between TAp73 and ΔEx2/3p73 accounts for its
oncogenic activity. Consistent with the induction of apop-
tosis after ΔNp73 knockdown, ASO-mediated suppres-
sion of ΔTAp73 isoforms was sufficient to abrogate
apoptosis resistance to chemotherapy mediated by ectop-
ically expressed ΔTAp73. Enhanced chemosensitivity by
inhibition of ΔTAp73 spliced isoforms was recently dem-
onstrated in neuroblastoma using the cyclooxygenase
inhibitor celecoxib, which blocks both ΔEx2/3p73 and
ΔEx2p73 without isoform selectivity [34].
One of the most required desirements for LNA-ASOs is
their efficient delivery to target cell nuclei. Polymers of
cationic polyethyleneimine are well-studied compounds
that improve the in vitro and in vivo penetrance of ASOs to
cells and tissues [35], yet PEI-mediated DNA transfer is
not tumor directed. Thus, we aimed at constructing tar-
geted non viral vectors based on magnetic force-guided
polyplexes by coating PEI/ASO to nanoparticles that allowPage 9 of 13
(page number not for citation purposes)
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tumor site. As a result, mice that received accumulating
intratumoral injections of MNB/PEI-ASO complex against
ΔEx2/3 showed a stronger degree of tumor growth inhibi-
tion than those treated only with PEI/ASO, indicating that
increased antisense activity, substantiated by a marked
induction of TAp73, correlates with higher transfection
efficiency in tumor cells. Since the release of p73/p53
tumor suppressor function from ΔTAp73-mediated inhi-
bition has been linked to chemosensitivity [36], the use of
oncogenic p73 ASOs as a therapeutic strategy for cancer
treatment could be further improved by combination
with other genotoxic agents.
Conclusion
We have developed LNA-modified ASOs that downregu-
late individual aberrantly expressed ΔEx2, ΔEx2/3, ΔN',
and ΔN p73 forms in neoplastic cells and growing tumors
Induction of apoptosis in WI-38 fibroblasts by ASO-specific inhibition of DNp73Fig re 4
Induction of apoptosis in WI-38 fibroblasts by ASO-specific inhibition of DNp73. (A) Cells cultured in medium con-
taining 1.5 μM doxorubicin (DOX) were stained with Hoechst 33342 at 48 hours after cotransfection. Apoptotic cells show 
the typical features of membrane blebbing, cell shrinkage, and nuclear condensation (upper panel). The amount of viable cells 
cotransfected with ΔEx2/3p73α or ΔNp73α in the absence and presence of specific ASO was counted at indicated time points 
after trypan blue exclusion. Black bars correspond to 50 μm. (B) Detection of caspase-3 activity of cells treated as in A. Bar 
graphs show the mean ± S.D. of three independent experiments. Asterisks denote statistical significant p-values: * (p < 0.05); ** 
(p < 0.005).
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Activity of PEI/ASO-116 in SK-Mel-29 cells and effect on tumor xenografts in vivoFigure 5
Activity of PEI/ASO-116 in SK-Mel-29 cells and effect on tumor xenografts in vivo. (A) Semiquantitative RT-PCR 
analysis of endogenous p73 isoforms in melanoma cells. (B) Quantification of ΔEx2/3p73 transcript levels in melanoma cells 
transfected with 250 nM PEI/ASO-116 by real-time PCR at indicated time points. Expression was normalized to RPS9. Fold 
changes are relative to ASO-nsc. Data represent the mean ± S.D. of three independent experiments. (C) BrdU incorporation 
of cells transfected with PEI/ASO-116- or ASO-sc on day 1 and 3 was measured by ELISA. Significant differences are labeled 
with asterisks (* p < 0.01; ** p < 0.005). (D) In vivo imaging of PEI/ASO complex 1, 8, and 24 h after intratumoral injection. The 
fluorescence image (pseudocolor) was overlaid on the photographic image. Intensity of fluorescent signal from Oregon green 
488 labeled ASO is shown in top and side view. (E) Relative tumor volumes (RTV) of SK-Mel-29 xenografts injected with PEI/
ASO (sc and 116) or MNB/PEI/ASO (M sc and M 116) at a daily interval (p < 0.001). Significant differences between M 116 and 
116 are labeled with asterisks (*p < 0.05). (F) ΔEx2/3p73 and TAp73 transcript levels in tumor tissues after 6 day treatment 
shown in E were quantitated by qRT-PCR. Expression was normalized to RPS9. Fold changes are relative to scrambled controls 























Molecular Cancer 2009, 8:61 http://www.molecular-cancer.com/content/8/1/61with high specificity. ASO-mediated modulation of
endogenous isoform expression resulted in tumor growth
inhibition in vivo accompanied by the induction of apop-
totic TAp73. The data of this study support the application
of NH2-truncated p73 inhibitors as valuable tools to
delineate their biological role in human cancers and as
anticancer agents.
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